Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase III trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease (NAFLD) and presumed nonalcoholic steatohepatitis.